Article Text

Download PDFPDF
Advancing evidence-based practice to improve patient care
  1. Andrea Cipriani1,
  2. Toshi A Furukawa2
  1. 1Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK;
  2. 2Department of Health Promotion and Human Behavior and of Clinical Epidemiology, Kyoto University Graduate School of Medicine, School of Public Health, Kyoto, Japan
  1. Correspondence to Dr Andrea Cipriani, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK;{at}

Statistics from

The new editorial board has now settled in the new position and, as anticipated, we have started working harder on EBMH. First, we would like to make clear to our readership the scope of this journal: introduce and promote the practices of evidence based medicine in mental health across the world.

This means that we are not interested in simply selecting and disseminating the best evidence by itself. In the scientific literature, a lot of information (sometimes too much and too often misleading) is continuously available and many websites or other sources keep updating, almost in real time, on the newest articles. We think the mission of EBMH is rather different. We want to help interested people learn how to select and use the best available evidence to answer their questions and materially improve their own clinical practice. This journal has to be seen (and built) as a tool to learn how to practice evidence-based-ly in the context of specific and diverse mental health clinical settings across the world. We don't think this scope is completely different from what it has been before. However, we wanted to make it very clear since the very beginning, because these are the grounds from which we want to start working together with our readership. EBMH editorial board thinks that all mental health professionals should inform their practice within the context of evidence-based medicine. This is not because evidence-based medicine is the best way to treat patients, but because it is the best way we have to treat patients. EBMH should move from the dusty shelf of a remote library to the messy desk of each one of us and become a tool for our daily work. We would like EBMH to stimulate a critical approach and a fruitful interaction between the editorial …

View Full Text


  • Competing interests TAF has received honoraria for speaking at CME meetings sponsored by Eli Lilly, Meiji, Mochida, MSD, Pfizer and Tanabe-Mitsubishi. He is diplomate of the Academy of Cognitive Therapy. He has received royalties from Igaku-Shoin, Seiwa-Shoten and Nihon Bunka Kagaku-sha. He is on advisory board for Sekisui Chemicals and Takeda Science Foundation. The Japanese Ministry of Education, Science, and Technology, the Japanese Ministry of Health, Labor and Welfare, and the Japan Foundation for Neuroscience and Mental Health have funded his research projects.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.